| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
BILLERICA, Mass.—Bruker has signed an agreement to acquireMichrom Bioresources Inc., a 20-year-old, privately owned company based inAuburn, Calif.
 
Michrom provides liquid chromatography (LC) instrumentation,accessories and consumables for applications in the life science, chemical andapplied markets. In particular, Michrom recently has launched the novel Advancenanoflow ultra-high performance liquid chromatography (UHPLC) system andproprietary CaptiveSpray Ionization (CSI) sources for coupling to massspectrometry (MS) in proteomics and other life-science applications.
 
Financial details of the transaction were not disclosed, andBruker declined to comment on the whys and wherefores of the acquisition untilthe closing, which is expected within weeks. But with Michrom's 2010 revenuehovering in the $3 million range, an immediate spike to sales and profits is anunlikely motivation. Instead, it appears that Michrom's UHPLC technology piquedBruker's interest.
 
In commenting on the agreement, Collin D'Silva, president ofBruker's Chemical & Applied Markets division, says that "Michrom's broadportfolio of novel technologies and high-performance products is highlycomplementary to our mass spectrometry products. In particular, Michrom's newhigh duty-cycle nanoflow UHPLC platform, along with their revolutionaryCaptiveSpray LC-MS interface, together will provide our customers withsignificant gains in throughput, sensitivity and robustness for proteomics andother nano and capillary flow LC-MS applications."
 
Michrom President Kerry Nugent expects the transaction tomake Michrom's products more widely available to global customers seeking thesekey novel technologies.
 
"With Bruker's Fremont, Calif., manufacturing infrastructureand well-developed global distribution channels, we will be able to makegreater strides to provide customers with advanced analytical solutions thatembody technologies based on our expertise in biochemistry and microfluidics,"he says. "I am very excited that the significant potential of our newtechnologies is now closer to being realized by more discerning customers."
 
Nugent is expected to join Bruker as senior vice presidentof liquid chromatography, and Bruker plans to retain all of Michrom's employeesas well.
 
The Advance nanoLC is a splitless nano-capillaryhigh-performance instrument that is designed to provide precise, reproducibleseparations from 100 nL/min to 50,000 nL/min with no hardware changes. Thesystem features < 25 nL delay volume and operates up to 10,000 PSI (70MPa),providing the ability to run long columns for extremely high resolution andeliminating both delay and re-equilibration times to maximize mass specutilization time.
 
CSI provides the next step in the evolution of LC/MS(0.1-100 µl/min), bridging the flow, sensitivity and robust operational gapbetween electro-spray ionization (ESI) and nanospray ionization (NSI). CSIutilizes a high-voltage, non-tapered capillary emitter attached to the vacuumof the MS, which pulls in gas around the emitter, funneling all the sample ionsinto the MS. Its plug-and-play operation requires no cameras or "xyz"alignment, providing ESI robustness with NSI sensitivity. 
 
CSI is used by proteomics researchers who want higherthroughput and/or robust operation for qualitative and quantitativeidentification, as well as by pharmaceutical scientists who need enhancedsensitivity without sacrificing robustness or throughput, Michrom states.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D rendering of motor neurons lit up with blue, purple, orange, and green coloring showing synapses against a black background.

Improving ALS research with pluripotent stem cell-derived models 

Discover new advancements in modeling amyotrophic lateral sclerosis.

Automating 3D cell selection

Discover precise automated tools for organoid and spheroid handling. 
An illustration of the tumor microenvironment, showing cancer cells, T cells, and nanoparticles interacting within a complex biological system

A closer look at the tumor microenvironment 

New technologies are allowing researchers to delve deeper into the complex tumor landscape.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue